酪氨酸激酶抑制增加FLT3-ITD的细胞表面定位并增强急性髓系白血病的FLT3靶向免疫治疗
该研究分析酪氨酸激酶抑制剂(TKI)对FLT3受体及其突变体定位的影响。TKI处理通过上调FLT3及FLT3-ITD和FLT3-D835Y突变体的糖基化增加表面表达。在T细胞介导的细胞毒性(TCMC)实验中,使用双特异性FLT3×CD3抗体构建体,联合TKI处理增强了FLT3-ITD阳性AML细胞系MOLM-13和MV4-11、患者来源异种移植细胞及原代患者样本的TCMC。
要点
- TKI处理增加FLT3-ITD和FLT3-D835Y突变体的细胞表面表达。
- TKI联合FLT3×CD3双特异性抗体增强FLT3-ITD阳性AML的TCMC。
- 该发现为TKI与FLT3靶向免疫治疗的合理联合提供了基础。
核心结论
- TKI处理通过上调FLT3及FLT3-ITD和FLT3-D835Y突变体的糖基化增加其表面表达。
- 在TCMC实验中,TKI联合双特异性FLT3×CD3抗体构建体增强了FLT3-ITD阳性AML细胞系、患者来源异种移植细胞及原代患者样本的细胞毒性。
- 该发现为TKI与FLT3靶向免疫治疗的合理联合提供了基础,可能使FLT3-ITD阳性AML患者获益。
研究设计与样本
- 研究分析了TKI对FLT3受体及其突变体定位的影响。
- 使用FLT3-ITD阳性AML细胞系MOLM-13和MV4-11、患者来源异种移植细胞及原代患者样本进行TCMC实验。
主要发现
- TKI处理增加FLT3及FLT3-ITD和FLT3-D835Y突变体的表面表达。
- 在TCMC实验中,使用双特异性FLT3×CD3抗体构建体,联合TKI处理增强了MOLM-13和MV4-11细胞系、患者来源异种移植细胞及原代患者样本的细胞毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in this setting as they are associated with unfavorable prognosis. Because of sequence-dependent protein conformational changes FLT3-ITD tends to autophosphorylate and displays a constitutive intracellular localization. Here, we analyzed the effect of tyrosine kinase inhibitors (TKIs) on the localization of the FLT3 receptor and its mutants. TKI treatment increased the surface expression through upregulation of FLT3 and glycosylation of FLT3-ITD and FLT3-D835Y mutants. In T cell-mediated cytotoxicity (TCMC) assays, using a bispecific FLT3 × CD3 antibody construct, the combination with TKI treatment increased TCMC in the FLT3-ITD-positive AML cell lines MOLM-13 and MV4-11, patient-derived xenograft cells and primary patient samples. Our findings provide the basis for rational combination of TKI and FLT3-directed immunotherapy with potential benefit for FLT3-ITD-positive AML patients.
引用
- Reiter K, Polzer H, Krupka C, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia. 2017. PMID: 28895560. doi:10.1038/leu.2017.257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。